Spero Therapeutics, a clinical-stage biopharmaceutical company, will announce its financial results for Q2 ended June 30, 2026, on August 12 after market close. The company will also provide a business and pipeline update during a conference call and webcast. Spero is advancing SP001, a next-generation immunology drug candidate targeting IgG4-related disease and other immune conditions. Investors can access the live webcast via the company’s website or by phone.
Grayscale's ZCSH ETF increased its Zcash holdings by 28.4% to 596,269 ZEC, representing about 3.52% of the total circulating supply, within weeks of its August 25, 2026 launch. This growth was driven entirely by in-kind transfers, primarily from Gray...
Strategy Inc., led by Michael Saylor, hinted at a potential new bitcoin purchase with a recent "orange" signal on its holdings chart, following a two-week pause in buying. The company currently holds 845,050 BTC valued at about $67.9 billion, with an...
ConocoPhillips is rated Buy as its strong production in the US Lower 48 and potential oil price gains outweigh elevated geopolitical risks from its international operations in Qatar, Libya, Iraq, and Syria. In Q2, the company showed strong execution ...
Ares Capital (ARCC) has proven resilience in the direct lending market over 22 years, successfully navigating major economic downturns like the 2008 financial crisis, the 2015–2016 energy slump, and the 2020 pandemic. Its disciplined underwriting and...
Mayville Engineering Company (MEC) was upgraded to a 'strong buy' following a 40.9% drop in its share price despite continued revenue growth and an increased revenue forecast of $620–$650 million for the year. The company benefits from strong demand ...
